Related Experiment Videos
Economic considerations in Alzheimer's disease
P D Meek1, K McKeithan, G T Schumock
1School of Pharmacy, University of Wisconsin at Madison, 53706-1515, USA.
Pharmacotherapy
|April 16, 1998
Summary
Alzheimer's disease (AD) is a major health concern, costing billions annually. Early medical treatment can offer economic benefits by improving patient and caregiver outcomes.
Area of Science:
- Gerontology
- Health Economics
- Neurodegenerative Diseases
Background:
- Alzheimer's disease (AD) represents a significant economic burden, ranking as the third most expensive illness in the U.S.
- The prevalence of AD is increasing due to societal aging, exacerbating its impact.
- AD costs encompass direct medical expenses, non-medical care, and indirect costs like lost productivity.
Purpose of the Study:
- To evaluate the economic impact and benefits of medical interventions for Alzheimer's disease.
- To analyze the pharmacoeconomic effects of drug therapy on AD management.
Main Methods:
- Review of economic costs associated with Alzheimer's disease.
- Pharmacoeconomic evaluations of drug therapies.
Main Results:
- Medical treatments demonstrate economic advantages by potentially slowing cognitive decline and delaying institutionalization.
- Drug therapy has shown positive impacts on reducing nursing home placement and caregiver time.
- Improvements in patient quality of life and caregiver productivity are associated with treatment.
Conclusions:
- Pharmacoeconomic evaluations support the use of drug therapy in managing Alzheimer's disease.
- Interventions for AD can yield substantial economic benefits by mitigating direct and indirect costs.
- Addressing the economic burden of Alzheimer's disease is crucial given its increasing prevalence.